# Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

> **NCT03145480** · PHASE2 · TERMINATED · sponsor: **Northwell Health** · enrollment: 3 (actual)

## Conditions studied

- Richter Syndrome

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Ibrutinib
- **OTHER:** CHOP

## Key facts

- **NCT ID:** NCT03145480
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-19
- **Primary completion:** 2018-09-28
- **Final completion:** 2018-09-28
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Investigator decision to close study
- **Last updated:** 2023-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03145480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03145480, "Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03145480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*